Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene's Q1 Revenues Rise

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene reported after the close of the market Tuesday that its first-quarter revenues increased to $119,000 from $34,000.

The company said that during the quarter it started a pilot launch of a urine-based molecular diagnostic test for human papillomavirus, it extended a planned offering of its urine-based oncogene mutation tests targeting the hepatitis B virus, and it expanded a clinical collaboration with the University of Texas MD Anderson Cancer Center to include the detection of transrenal BRAF mutations in the urine of patients with advanced metastatic cancers.

The San Diego-based firm posted a net loss of $1.1 million, or $.07 per share, for the three months ended March 31, compared to a loss of $1.2 million, or $.11 per share, for Q1 2012.

The company said that the decrease in net loss was primarily due to a change in the fair market value of derivative instruments, but added that the reduction was offset by the increase in operating expenses.

Trovagene's R&D spending swelled to $802,000 from $337,000 year over year, and its general and administrative costs more than doubled to $1.7 million from $827,000.

Trovagene finished the quarter with $9.2 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.